about
Global Emerging HEmophilia Panel (GEHEP): A Multinational Collaboration for Advancing Hemophilia Research and Treatment[Romiplostim: an advance in the treatment of idiopathic thrombocytopenic purpura].Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.Use of eltrombopag after romiplostim in primary immune thrombocytopenia.Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study.Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain.Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors.Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.Adult severe haemophilia A patients under long-term prophylaxis with factor VIII in routine clinical practice.Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey.Hip Replacement Surgery in 14-Year-Old Girl with Factor V Deficiency: Haemostatic Treatment and Thromboprophylaxis.Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm.Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors.Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project.Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT®Moderate and severe haemophilia in Spain: An epidemiological updateManagement of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group
P50
Q26864751-DE444B72-4647-4E8E-B58A-5AE274D095DDQ33394402-3CDC024F-E076-4882-8727-2ED4F0477CAAQ33418722-0DA15161-75D5-4B22-9FE0-763AE7683B86Q33419404-3A77D6B6-6F95-45EA-B61B-63435FB010E9Q33441053-C69E715B-B64B-4C72-8C43-10035757DDEDQ33443533-4E76F52C-DA19-4DDB-9A77-B8C9B6384EB7Q38682218-7C878033-96C6-4829-B690-29E2CBD87A1EQ41099388-CE38B4D9-73EC-4A4E-A08C-F34E7ABF1D80Q41230386-681289DC-D8DA-448A-998C-9A05F98CAC3FQ41417808-EF463ABB-985F-4833-89F1-67C7073903C5Q42081734-E3F2AC5B-891B-4816-96D7-6A9808900649Q50123382-14CC7226-5F43-4312-A86A-EE29E716F196Q53276522-DAAFD68B-93D5-4F23-A9BD-D5593A460E61Q55431354-03BBA21E-8C3F-4189-8C91-C111D9697382Q57664197-73F03AF9-6139-4ECF-BFB7-87364FC2C752Q57664200-FB8B2BB6-FDD4-4F2A-A378-3C393AA22E84Q90169375-0DD938ED-5655-4534-BC8D-3262A83B9BBD
P50
description
Spaans onderzoeker
@nl
researcher ORCID id 0000-0001-9083-855X
@en
name
M.E. Mingot-Castellano
@ast
M.E. Mingot-Castellano
@en
M.E. Mingot-Castellano
@es
M.E. Mingot-Castellano
@nl
M.E. Mingot-Castellano
@sl
type
label
M.E. Mingot-Castellano
@ast
M.E. Mingot-Castellano
@en
M.E. Mingot-Castellano
@es
M.E. Mingot-Castellano
@nl
M.E. Mingot-Castellano
@sl
altLabel
M.E. Mingot Castellano
@en
prefLabel
M.E. Mingot-Castellano
@ast
M.E. Mingot-Castellano
@en
M.E. Mingot-Castellano
@es
M.E. Mingot-Castellano
@nl
M.E. Mingot-Castellano
@sl
P106
P1153
6507406121
P27
P31
P496
0000-0001-9083-855X